Lane R

Janssen Research & Development, LLC, a Johnson & Johnson company, Titusville, New Jersey.

9 papers · ORCID

ArticleKetamine

Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.

Kosik-Gonzalez C, Fu DJ, Chen LN +6

Europe PMC2026
ArticleKetamine

Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study.

Zaki N, Chen LN, Lane R +7

Europe PMC2026
ArticleKetamine

Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.

Canuso CM, Bossie C, Fu DJ +12

Europe PMC2025
ArticleKetamine

Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.

Janik A, Qiu X, Lane R +8

Europe PMC2025
ArticleKetamine

Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study.

Zaki N, Chen LN, Lane R +10

Europe PMC2025
ArticleKetamine

Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.

Kosik-Gonzalez C, Fu DJ, Chen LN +6

Europe PMC2026
ArticleKetamine

Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies.

Morrison RL, Singh J, Daly E +8

Europe PMC2024
ArticleKetamine

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA.

Chen X, Hou X, Bai D +5

Europe PMC2023
ArticleKetamine

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.

Chen G, Chen L, Zhang Y +9

Europe PMC2022